Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Drug Category : Array
Conference Category : Array
Lead Author : Fox E, et al.
Published Date : 19/07/2019
Download Link : https://www.tgtherapeutics.com/2019%20EAN%20TGTX%20Phase%202%20Ubli.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top